Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinoids + gabapentin
- Development stage
- Preclinical
- Lead developer
- Incannex Healthcare
- Modality
- Small Molecules
- Administration
- Buccal, Oral
01
Overview
cannabinoids + gabapentin is a combination drug product under development by APIRx Pharma Sciences for the management of pain and neuropathic pain. The product is formulated as a medicated chewing gum designed for buccal delivery, which may offer improved bioavailability and faster onset of action compared to traditional oral tablets. Gabapentin acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby reducing the release of excitatory neurotransmitters. The cannabinoid component typically targets CB1 and CB2 receptors to modulate pain signaling and inflammatory responses. This combination aims to provide synergistic analgesic effects by targeting multiple pathways involved in chronic and neuropathic pain. Currently, the project is in the preclinical stage with patent applications pending.
- Other names
- Chewing gum with cannabinoids + gabapentin
02
Targets
CNR1 (Cannabinoid receptor 1)THBS2 (Thrombospondin-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on cannabinoids + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinoids + gabapentin.